This website uses cookies to improve your experience.

Cookie policy

Ribociclib plus endocrine therapy in early breast cancer.

Slamon D, Lipatov O, Nowecki Z, McAndrew N, Ika-Budny BK, Stroyakovskiy D et al.

N Engl J Med 2024; 390: 1080-1091.

The addition of ribociclib to standard aromatase inhibitor treatment for women with hormone receptor positive, HER2-negative early breast cancer significantly improved 3-year disease-free survival from 87.1 to 90.4 per cent (P=0.003) in this large international study.

Comment: More information towards optimized adjuvant therapy.

Read paper


Part of the charitable activity of the Foundation, BJS Academy is an online educational resource for current and future surgeons.

The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.

Discover the Academy
Surgeon Training & Surgeons in Surgery